Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBATROSS: Galicaftor in Ivacaftor-treated Cystic Fibrosis
NCT03045523Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of galicaftor in cystic fibrosis (CF), sponsored by Galapagos NV. Started Jan 2017; status: completed.
02
Drugs
galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03045523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045523.